Nasdaq

PacBio announces SPRQ chemistry for Revio sequencing systems

PacBio (PACB) announced SPRQ, an improved sequencing chemistry for its Revio long-read sequencing system. The new chemistry will reduce Revio DNA input requirements ...
Seeking Alpha

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500

MENLO PARK, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PacBio (PACB) (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced SPRQ, an improved ...
Seeking Alpha

PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities

MENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (PACB), developer of the world's most advanced sequencing technologies, today announced innovations to its Revio and Vega platforms ...

PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, and Covaris, a PerkinElmer company and leader in sample preparation technologies, today announced a ...

Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

How The PacBio (PACB) Story Is Shifting Between Long Term Potential And Near Term Risks

Pacific Biosciences of California is back in focus after an updated fair value estimate of $2.58 is being weighed against a fresh Street price target of $1.50. That gap reflects a debate you should ...